enanta pharmaceuticals inc - ENTA
ENTA
Close Chg Chg %
14.14 0.59 4.17%
Closed Market
14.73
+0.59 (4.17%)
Volume: 254.94K
Last Updated:
Dec 12, 2025, 4:00 PM EDT
Company Overview: enanta pharmaceuticals inc - ENTA
ENTA Key Data
| Open $14.13 | Day Range 13.99 - 14.95 |
| 52 Week Range 4.09 - 15.34 | Market Cap $414.76M |
| Shares Outstanding 28.86M | Public Float 27.42M |
| Beta 0.97 | Rev. Per Employee N/A |
| P/E Ratio N/A | EPS -$3.84 |
| Yield 0.00% | Dividend N/A |
| EX-DIVIDEND DATE | SHORT INTEREST N/A |
| AVERAGE VOLUME 303.60K |
ENTA Performance
| 1 Week | 0.89% | ||
| 1 Month | 22.14% | ||
| 3 Months | 77.90% | ||
| 1 Year | 144.28% | ||
| 5 Years | -66.58% |
ENTA Analyst Ratings
- Sell
- Under
- Hold
- Over
- Buy
Number of Ratings
8
Full Ratings ➔
About enanta pharmaceuticals inc - ENTA
Enanta Pharmaceuticals, Inc. is a biotechnology company, which engages in the discovery and development of small molecule drugs for the treatment of viral infections and liver diseases. It produces clinical candidates which targets respiratory syncytial virus (RSV), hepatitis B virus (HBV), and non-alcoholic steatohepatitis (NASH) diseases. The firm also conducts research in human metapneumovirus (hMPV) and SARS-CoV-2 (COVID-19). The company was founded by Peter O. Kliem Martin Karplus, James Hogle, Gerard Wagner, Peter M. Howley, and Gregory L. Verdine in 1995 and is headquartered in Watertown, MA.
ENTA At a Glance
Enanta Pharmaceuticals, Inc.
4 Kingsbury Avenue
Watertown, Massachusetts 02472
| Phone | 1-617-607-0800 | Revenue | 65.32M | |
| Industry | Pharmaceuticals: Major | Net Income | -81,889,000.00 | |
| Sector | Health Technology | Employees | 120 | |
| Fiscal Year-end | 09 / 2026 | |||
| View SEC Filings |
ENTA Valuation
| P/E Current | N/A |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | N/A |
| Price to Sales Ratio | 3.91 |
| Price to Book Ratio | 3.956 |
| Price to Cash Flow Ratio | N/A |
| Enterprise Value to EBITDA | -3.313 |
| Enterprise Value to Sales | 4.096 |
| Total Debt to Enterprise Value | 0.751 |
ENTA Efficiency
| Revenue/Employee | 544,366.667 |
| Income Per Employee | -682,408.333 |
| Receivables Turnover | 9.492 |
| Total Asset Turnover | 0.191 |
ENTA Liquidity
| Current Ratio | 4.208 |
| Quick Ratio | 4.208 |
| Cash Ratio | 3.89 |
ENTA Profitability
| Gross Margin | 92.98 |
| Operating Margin | -130.655 |
| Pretax Margin | -127.899 |
| Net Margin | -125.358 |
| Return on Assets | -23.961 |
| Return on Equity | -84.626 |
| Return on Total Capital | -30.812 |
| Return on Invested Capital | -29.734 |
ENTA Capital Structure
| Total Debt to Total Equity | 310.67 |
| Total Debt to Total Capital | 75.65 |
| Total Debt to Total Assets | 68.686 |
| Long-Term Debt to Equity | 258.356 |
| Long-Term Debt to Total Capital | 62.911 |
- Income Statement
- Balance Sheet
- Cash Flow Statement
Annual Financials for Enanta Pharmaceuticals Inc - ENTA
Collapse All in section
| All values USD millions. | 2022 | 2023 | 2024 | 2025 | 5-year trend |
|---|---|---|---|---|---|
Sales/Revenue
| 86.16M | 79.20M | 67.64M | 65.32M | |
Sales Growth
| -11.24% | -8.07% | -14.61% | -3.42% | |
Cost of Goods Sold (COGS) incl D&A
| 2.97M | 2.37M | 2.34M | 4.59M | |
COGS excluding D&A
| - | - | - | - | - |
Depreciation & Amortization Expense
| 2.97M | 2.37M | 2.34M | 4.59M | |
Depreciation
| 2.97M | 2.37M | 2.34M | 4.59M | |
Amortization of Intangibles
| - | - | - | - | - |
COGS Growth
| - | -20.25% | -1.48% | +96.32% | |
Gross Income
| 83.19M | 76.83M | 65.30M | 60.74M | |
Gross Income Growth
| - | -7.64% | -15.01% | -6.98% | |
Gross Profit Margin
| +96.55% | +97.01% | +96.55% | +92.98% |
| 2022 | 2023 | 2024 | 2025 | 5-year trend | |
|---|---|---|---|---|---|
SG&A Expense
| 207.03M | 214.04M | 186.99M | 146.09M | |
Research & Development
| 164.52M | 163.52M | 131.48M | 106.74M | |
Other SG&A
| 42.51M | 50.52M | 55.51M | 39.35M | |
SGA Growth
| +1.83% | +3.39% | -12.64% | -21.87% | |
Other Operating Expense
| - | - | - | - | - |
Unusual Expense
| - | (83.00K) | (73.00K) | (39.00K) | |
EBIT after Unusual Expense
| (123.76M) | (137.21M) | (121.62M) | (85.31M) | |
Non Operating Income/Expense
| 1.57M | 11.36M | 14.77M | 9.44M | |
Non-Operating Interest Income
| 1.57M | 11.36M | 14.77M | 9.44M | |
Equity in Earnings of Affiliates
| - | - | - | - | - |
Interest Expense
| - | 5.15M | 10.94M | 7.68M | |
Interest Expense Growth
| - | - | +112.51% | -29.79% | - |
Gross Interest Expense
| - | 5.15M | 10.94M | 7.68M | |
Interest Capitalized
| - | - | - | - | - |
Pretax Income
| (122.19M) | (131.00M) | (117.79M) | (83.55M) | |
Pretax Income Growth
| -13.58% | -7.21% | +10.08% | +29.07% | |
Pretax Margin
| -141.82% | -165.39% | -174.15% | -127.90% | |
Income Tax
| (433.00K) | 2.82M | (1.74M) | (1.66M) | |
Income Tax - Current - Domestic
| (449.00K) | 2.82M | (1.74M) | (1.66M) | |
Income Tax - Current - Foreign
| - | - | - | - | - |
Income Tax - Deferred - Domestic
| - | - | - | 16.00K | - |
Income Tax - Deferred - Foreign
| - | - | - | - | - |
Income Tax Credits
| - | - | - | - | - |
Equity in Earnings of Affiliates
| - | - | - | - | - |
Other After Tax Income (Expense)
| - | - | - | - | - |
Consolidated Net Income
| (121.75M) | (133.82M) | (116.05M) | (81.89M) | |
Minority Interest Expense
| - | - | - | - | - |
Net Income
| (121.75M) | (133.82M) | (116.05M) | (81.89M) | |
Net Income Growth
| -54.13% | -9.91% | +13.28% | +29.43% | |
Net Margin Growth
| -141.31% | -168.95% | -171.58% | -125.36% | |
Extraordinaries & Discontinued Operations
| - | - | - | - | - |
Discontinued Operations
| - | - | - | - | - |
Net Income After Extraordinaries
| (121.75M) | (133.82M) | (116.05M) | (81.89M) | |
Preferred Dividends
| - | - | - | - | - |
Net Income Available to Common
| (121.75M) | (133.82M) | (116.05M) | (81.89M) | |
EPS (Basic)
| -5.9096 | -6.3816 | -5.485 | -3.8381 | |
EPS (Basic) Growth
| -50.90% | -7.99% | +14.05% | +30.03% | |
Basic Shares Outstanding
| 20.60M | 20.97M | 21.16M | 21.34M | |
EPS (Diluted)
| -5.9096 | -6.3816 | -5.485 | -3.8381 | |
EPS (Diluted) Growth
| -50.90% | -7.99% | +14.05% | +30.03% | |
Diluted Shares Outstanding
| 20.60M | 20.97M | 21.16M | 21.34M | |
EBITDA
| (120.87M) | (134.84M) | (119.36M) | (80.76M) | |
EBITDA Growth
| -13.77% | -11.55% | +11.48% | +32.33% | |
EBITDA Margin
| -140.29% | -170.24% | -176.47% | -123.63% |
Snapshot
| Average Recommendation | BUY | Average Target Price | 19.125 | |
| Number of Ratings | 8 | Current Quarters Estimate | -0.778 | |
| FY Report Date | 12 / 2025 | Current Year's Estimate | -3.041 | |
| Last Quarter’s Earnings | -0.87 | Median PE on CY Estimate | N/A | |
| Year Ago Earnings | -3.84 | Next Fiscal Year Estimate | -2.502 | |
| Median PE on Next FY Estimate | N/A |
Earnings Per Share
| This Quarter | Next Quarter | This Fiscal | Next Fiscal | |
|---|---|---|---|---|
| # of Estimates | 4 | 4 | 7 | 5 |
| Mean Estimate | -0.78 | -0.75 | -3.04 | -2.50 |
| High Estimates | -0.53 | -0.54 | -2.18 | -1.44 |
| Low Estimate | -1.11 | -1.17 | -4.47 | -3.82 |
| Coefficient of Variance | -37.10 | -39.85 | -27.42 | -36.19 |
Analysts Recommendations
| Current | 1 Month Ago | 3 Months Ago | |
|---|---|---|---|
| BUY | 6 | 6 | 5 |
| OVERWEIGHT | 1 | 1 | 1 |
| HOLD | 1 | 1 | 1 |
| UNDERWEIGHT | 0 | 0 | 0 |
| SELL | 0 | 0 | 0 |
| MEAN | Buy | Buy | Buy |
SEC Filings for Enanta Pharmaceuticals Inc - ENTA
| Filing Date | Type | Category | Amended |
|---|---|---|---|
| No results | |||
Insider Actions for Enanta Pharmaceuticals Inc - ENTA
| Date | Name | Shares | Transaction | Value |
|---|---|---|---|---|
| Mar 17, 2025 | Lesley Russell Director | 15,700 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Mar 17, 2025 | Kristine Peterson Director | 15,700 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Mar 17, 2025 | Yujiro S. Hata Director | 15,700 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Mar 17, 2025 | Terry C. Vance Director | 15,700 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Mar 17, 2025 | Bruce Leonard Andrews Carter Director | 15,700 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Mar 17, 2025 | Mark G. Foletta Director | 15,700 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Feb 17, 2025 | Jay R. Luly President and CEO; Director | 872,138 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Feb 17, 2025 | Jay R. Luly President and CEO; Director | 864,654 | Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $5.59 per share | 4,833,415.86 |
| Feb 17, 2025 | Yat Sun Or Chief Scientific Officer | 378,859 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Feb 17, 2025 | Yat Sun Or Chief Scientific Officer | 374,535 | Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $5.59 per share | 2,093,650.65 |
| Feb 17, 2025 | Paul J. Mellett Chief Fin. & Admin Officer | 95,884 | Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $5.59 per share | 535,991.56 |
| Feb 17, 2025 | Paul J. Mellett Chief Fin. & Admin Officer | 99,210 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Feb 17, 2025 | Tara L. Kieffer Chief Product Strategy Officer | 36,805 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Feb 17, 2025 | Tara L. Kieffer Chief Product Strategy Officer | 33,479 | Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $5.59 per share | 187,147.61 |
| Feb 17, 2025 | Brendan Luu Chief Business Officer | 43,547 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Feb 17, 2025 | Brendan Luu Chief Business Officer | 40,221 | Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $5.59 per share | 224,835.39 |
| Feb 17, 2025 | Scott T. Rottinghaus Chief Medical Officer | 27,668 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Feb 17, 2025 | Scott T. Rottinghaus Chief Medical Officer | 24,807 | Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $5.59 per share | 138,671.13 |